Koya N - Search Results

1

Human peripheral eosinophils express functional interferon-gamma receptors (IFN-gammaR).

Ishihara C, Ochiai K, Kagami M, Takashahi H, Matsuyama G, Yoshida S, Tomioka H, Koya N. Ishihara C, et al. Among authors: koya n. Clin Exp Immunol. 1997 Dec;110(3):524-9. doi: 10.1046/j.1365-2249.1997.4511469.x. Clin Exp Immunol. 1997. PMID: 9409660 Free PMC article.

2

Heterogeneous expression of tumor necrosis factor-alpha receptors I and II on human peripheral eosinophils.

Matsuyama G, Ochiai K, Ishihara C, Kagami M, Tomioka H, Koya N. Matsuyama G, et al. Among authors: koya n. Int Arch Allergy Immunol. 1998 Sep;117 Suppl 1:28-33. doi: 10.1159/000053567. Int Arch Allergy Immunol. 1998. PMID: 9758893

3

Interferon-gamma receptor beta-chain expression and formation of alpha- and beta-chain complexes after receptor conjugation on human peripheral eosinophils.

Ishiharu C, Ochiai K, Kagami M, Matsuyama G, Koya N, Tomioka H. Ishiharu C, et al. Among authors: koya n. Int Arch Allergy Immunol. 1998 Sep;117 Suppl 1:72-6. doi: 10.1159/000063280. Int Arch Allergy Immunol. 1998. PMID: 9758903

4

Role of JAK2 signal transductional pathway in activation and survival of human peripheral eosinophils by interferon-gamma (IFN-gamma).

Ochiai K, Tanabe E, Ishihara C, Kagami M, Sugiyama T, Sueishi M, Koya N, Tomioka H. Ochiai K, et al. Among authors: koya n. Clin Exp Immunol. 1999 Dec;118(3):340-3. doi: 10.1046/j.1365-2249.1999.01068.x. Clin Exp Immunol. 1999. PMID: 10594549 Free PMC article.

5

PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.

Fujimura A, Nakayama K, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Umebayashi M, Koya N, Morisaki T, Nakagawa T, Onishi H. Fujimura A, et al. Among authors: koya n. Cancer Immunol Immunother. 2019 Oct;68(10):1649-1660. doi: 10.1007/s00262-019-02403-y. Epub 2019 Sep 27. Cancer Immunol Immunother. 2019. PMID: 31562536 Free PMC article.

6

Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.

Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I, Katano M. Morisaki T, et al. Among authors: koya n. Anticancer Res. 2011 Jul;31(7):2505-10. Anticancer Res. 2011. PMID: 21873167

7

Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.

Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M. Morisaki T, et al. Among authors: koya n. Anticancer Res. 2012 Jun;32(6):2249-56. Anticancer Res. 2012. PMID: 22641659

8

A new method for rapid cytotoxic T-lymphocyte induction using a multiple cytokine cocktail.

Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Katano M, Morisaki T. Onishi H, et al. Among authors: koya n. Anticancer Res. 2012 Jun;32(6):2385-90. Anticancer Res. 2012. PMID: 22641679

9

Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.

Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M. Morisaki T, et al. Among authors: koya n. Anticancer Res. 2013 Apr;33(4):1387-95. Anticancer Res. 2013. PMID: 23564777

10

The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer.

Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M. Onishi H, et al. Among authors: koya n. Cancer Immunol Immunother. 2013 Jun;62(6):1029-39. doi: 10.1007/s00262-013-1419-5. Epub 2013 Apr 17. Cancer Immunol Immunother. 2013. PMID: 23591983 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters